LANA HULING: Open Payments
NPI 1730712217 · HARVEY, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$886 in 34 payments from 11 companies in 2025. Trend: 2023 $459 · 2024 $453 · 2025 $886
Food & beverage: $886
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 15 | $313 |
| Gilead Sciences, Inc. | 3 | $176 |
| Indivior Inc. | 2 | $79 |
| Neurocrine BioSciences, Inc. | 2 | $71 |
| E.R. Squibb & Sons, L.L.C. | 3 | $62 |
| Otsuka America Pharmaceutical, Inc. | 2 | $60 |
| Braeburn Inc. | 2 | $33 |
| Teva Pharmaceuticals USA, Inc. | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $23 |
| Exact Sciences Corporation | 1 | $20 |
Products named: CAPLYTA, Epclusa, SUBLOCADE, INGREZZA, COBENFY, REXULTI, BRIXADI, AUSTEDO XR.
Industry payments across LA — which companies pay providers there.
